pipeline hero

Summary and Pipeline

We aim to discover and develop medicines that are transformational for patients

Our programs span discovery-stage to late-stage development and cover a range of high-value indications including SerpinPC in hemophilia, orexin receptor 2 agonist program in sleep-wake disorders, and LockBody® technology platform in oncology.


We aim to pursue programs we believe could be first-in-class / best-in-class and where there is prior learning in human genetics or precedented human activity for a pathway of interest. Our approach is to pursue the best assets in a capital efficient manner and rapidly progress our programs through development, evaluating the unique biological advantage of our product candidates.


Centessa’s team is made up of pioneers in their fields working to advance our core programs. Read more on the inspiring stories of the continuing journeys from vision to transformational medicines below.

Realizing Our Vision

We are working to discover unique opportunities to potentially address key medical needs

Heros 07

SerpinPC in Hemophilia

Our hemophilia program has deep roots in the experiences of Dr. Trevor Baglin, an accomplished hematologist and Global Head of Hemophilia at Centessa. He was both inspired and driven to develop a drug that has the potential to change the current treatment paradigm for individuals living with hemophilia. 


Click below to learn more about how our novel candidate, SerpinPC, has been designed with the potential to fulfill existing unmet needs.

Heros 08

Orexin Receptor 2 Agonist Program in Sleep-Wake Disorders

Trained as a bioengineer, Dr. Mario Alberto Accardi, President of the Centessa Orexin Program, saw the opportunity to use structure-based drug design to disrupt the conventional approach to treating sleep-wake disorders.


Click below to learn more about our orexin receptor 2 agonist program for sleep-wake disorders and other neurological conditions.

Heros 08
LB locked nolabel

LockBody® Technology Platform in Oncology

Dr. William Finlay, President of the Centessa LockBody Program and a widely published expert on antibody engineering, developed the LockBody® technology platform with the goal to redefine immuno-oncology treatment for patients with cancer.

Click below to learn more about our novel LockBody® platform in oncology.  


Potential first-in-class/best-in-class medicines 




Phase 1

Phase 2


Activated Protein C (APC) Inhibitor
Hemophilia B

Fast Track Designation; Orphan Drug Designation

Orexin Receptor 2 Agonist
Narcolepsy Type 1 (NT1) and Other Sleep-Wake Disorders
PD-L1xCD47 LockBody® 
Solid Tumors

Centessa has other early-stage programs not reflected on this page.

Screenshot 2024 02 29 at 7.08.07 PM

Centessa’s mission is to discover and develop medicines that are transformational for patients. View our Expanded Access Policy for investigational medical products.

Scroll to Top
pipeline chart header registrational white

SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence

Hemophilia B